Insider Insights
01.02.2022
New restrictions for Prolia

The study showed that 20 - 25% of all prescriptions for the drug were not in line with the drug's au...

Read more
Insider Insights
01.02.2022
Committee recommends rejecting Rx to non-Rx reques

The committee’s recommendations are forwarded to the Federal Ministry of Health for consideration.

Read more
Articles
01.02.2022
Changes to NICE's health technology evaluation

This reforms have been welcomed by the industry as they should support faster access to medicines as...

Read more
Insider Insights
01.02.2022
Proposals aimed at building together our future

The association proposes concentrating efforts around four primary objectives.

Read more
Insider Insights
01.02.2022
Orphan drugs undergo early benefit assessment

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo ear...

Read more
Insider Insights
01.02.2022
NICEs new methods and processes manual

The National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...

Read more
Articles
25.01.2022
PMA Perspectives Q1 2022

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...

Read more
Articles
17.01.2022
COVID-19 Two Year Review

As we enter 2022, we are approaching the two-year anniversary of the COVID-19 pandemic spreading acr...

Read more
Articles
10.01.2022
Conducting a HTA review

Reviewing previous HTA submissions can provide valuable insights that can help manufacturers prepare...

Read more
Articles
20.12.2021
The end of higher drug prices in the US

In the US, an Act recently passed through the House of Representatives which plans to expand afforda...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.